Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of two poster presentations that focus on the use of Copanlisib for relapsed or refractory follicular lymphoma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Poster #7535: Copanlisib in patients with relapsed or refractory follicular lymphoma
Poster #7536: Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Advertisement